471 related articles for article (PubMed ID: 10706628)
1. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
2. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
Dembic Z; Hofgaard PO; Omholt H; Bogen B
Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
[TBL] [Abstract][Full Text] [Related]
3. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells.
Lauritzsen GF; Bogen B
Cell Immunol; 1993 Apr; 148(1):177-88. PubMed ID: 8098665
[TBL] [Abstract][Full Text] [Related]
4. Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.
Corthay A; Lundin KU; Lorvik KB; Hofgaard PO; Bogen B
Cancer Res; 2009 Jul; 69(14):5901-7. PubMed ID: 19567679
[TBL] [Abstract][Full Text] [Related]
5. Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T-cell immunity in vivo.
Kleindienst P; Brocker T
Immunology; 2005 Aug; 115(4):556-64. PubMed ID: 16011524
[TBL] [Abstract][Full Text] [Related]
6. A mouse model for immunotherapy of myeloma.
Bogen B
Hematol J; 2002; 3(5):224-9. PubMed ID: 12391539
[TBL] [Abstract][Full Text] [Related]
7. Primary antitumor immune response mediated by CD4+ T cells.
Corthay A; Skovseth DK; Lundin KU; Røsjø E; Omholt H; Hofgaard PO; Haraldsen G; Bogen B
Immunity; 2005 Mar; 22(3):371-83. PubMed ID: 15780993
[TBL] [Abstract][Full Text] [Related]
8. Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma.
Bogen B
Eur J Immunol; 1996 Nov; 26(11):2671-9. PubMed ID: 8921954
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.
Herkel J; Jagemann B; Wiegard C; Lazaro JF; Lueth S; Kanzler S; Blessing M; Schmitt E; Lohse AW
Hepatology; 2003 May; 37(5):1079-85. PubMed ID: 12717388
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells.
Guéry JC; Adorini L
J Immunol; 1995 Jan; 154(2):536-44. PubMed ID: 7529278
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
12. CD40 is necessary for activation of naïve T cells by a dendritic cell line in vivo but not in vitro.
Haase C; Michelsen BK; Jørgensen TN
Scand J Immunol; 2004 Mar; 59(3):237-45. PubMed ID: 15030573
[TBL] [Abstract][Full Text] [Related]
13. UVB-irradiated dendritic cells are impaired in their APC function and tolerize primed Th1 cells but not naive CD4+ T cells.
Denfeld RW; Hara H; Tesmann JP; Martin S; Simon JC
J Leukoc Biol; 2001 Apr; 69(4):548-54. PubMed ID: 11310840
[TBL] [Abstract][Full Text] [Related]
14. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
[TBL] [Abstract][Full Text] [Related]
15. Intercellular exchange of class II major histocompatibility complex/peptide complexes is a conserved process that requires activation of T cells but is constitutive in other types of antigen presenting cell.
Patel DM; Mannie MD
Cell Immunol; 2001 Dec; 214(2):165-72. PubMed ID: 12088415
[TBL] [Abstract][Full Text] [Related]
16. Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer.
Corthay A; Lorvik KB; Bogen B
Scand J Immunol; 2011 Jun; 73(6):527-30. PubMed ID: 21388431
[TBL] [Abstract][Full Text] [Related]
17. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
[TBL] [Abstract][Full Text] [Related]
18. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells.
Röhn TA; Schadendorf D; Sun Y; Nguyen XD; Roeder D; Langen H; Vogt AB; Kropshofer H
Eur J Immunol; 2005 Oct; 35(10):2826-39. PubMed ID: 16163671
[TBL] [Abstract][Full Text] [Related]
19. Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo.
Levin D; Constant S; Pasqualini T; Flavell R; Bottomly K
J Immunol; 1993 Dec; 151(12):6742-50. PubMed ID: 7903097
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
Ghosh SK; White LM; Ghosh R; Bankert RB
J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
